Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR

Oncologist. 2015 May;20(5):570. doi: 10.1634/theoncologist.2013-0419erratum.
No abstract available

Publication types

  • Published Erratum